• Novel Ziprasidone Impurity: Structure and Significance

  2026-08-27

  The reference study identified and structurally characterized a previously unreported methylene ziprasidone dimer that appeared during scale-up of ziprasidone hydrochloride manufacture. By combining preparative HPLC with high-resolution mass spectrometry and multidimensional NMR, the authors established the impurity structure and proposed a plausible formation pathway, providing a practical framework for pharmaceutical impurity control.

• MTT Assay Workflow for Kidney Fibrosis Research

  2026-08-26

  Use MTT to distinguish treatment-related cytotoxicity from metabolic remodeling in renal tubular cell models. This practical workflow connects epirubicin–B56δ research with reproducible colorimetric viability testing, including setup, controls, optimization, and troubleshooting.

• FXR–KLF11 Signaling in Contrast AKI

  2026-08-26

  The reference study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by suppressing JAK2/STAT3 signaling. Its combination of mouse modeling, HK-2 cell experiments, transcriptomics, promoter assays, and genetic perturbation provides a mechanistic framework for evaluating CDCA in renal injury research.

• Nanoparticle Uptake Pathways in Human Corneal Cells

  2026-08-25

  Azadi and David examined how nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells using engineered PLGA nanoparticles and a mucosal in vitro model. The study linked particle properties to pathway-level behavior, identifying energy-dependent uptake dominated by macropinocytosis and caveolae-mediated endocytosis rather than phagocytosis.

• Septin4, VHL, and HIF-1α in Cardiomyocyte Apoptosis

  2026-08-25

  The 2021 Cell Death Discovery study identifies HIF-1α as a Septin4-interacting protein and shows that Septin4 promotes VHL-dependent HIF-1α degradation during hypoxic cardiomyocyte injury. These findings place Septin4 upstream of a key oxygen-adaptation pathway and suggest a mechanistic explanation for its proapoptotic activity in myocardial hypoxia.

• Temozolomide in DNA Repair and Glioma Research

  2026-08-24

  Temozolomide provides a controlled methylation-based DNA damage model for glioma, cancer biology, and chemotherapy resistance studies. This guide translates its chemistry into practical dosing, combination, readout, and troubleshooting workflows, including ATRX-informed assays inspired by recent high-grade glioma research.

• Tetraethylammonium chloride in Cell Assays

  2026-08-24

  This scenario-based guide explains how Tetraethylammonium chloride, SKU B7262, can strengthen mechanistic interpretation in cell viability, proliferation, cytotoxicity, and potassium-channel studies. It connects assay design, solution handling, data interpretation, and vendor qualification to documented chemical and quality-control information.

• ARCA Cy5 EGFP mRNA: Assay Architecture

  2026-08-23

  ARCA Cy5 EGFP mRNA (5-moUTP) enables researchers to separate cellular delivery from protein expression in a single reporter system. This guide presents an assay-design framework for interpreting Cy5, EGFP, trafficking, translation, and immune-response data in mammalian cells.

• E-64d at the Proteostasis Decision Point

  2026-08-22

  E-64d is a membrane-permeable cysteine protease inhibitor that helps separate calpain- and cathepsin-dependent phenotypes from autophagic or proteasomal degradation. This article translates a recent Arabidopsis autophagy study into practical assay decisions without treating E-64d as a nonspecific substitute for genetic pathway analysis.

• Betaine Hydrochloride for Translational Assays

  2026-08-22

  Betaine hydrochloride can be used as a deliberately controlled variable in enzyme, protease, cell culture, and molecular biology workflows—not merely as a soluble reagent. This guide connects practical assay design with the inflammation-focused esophageal cancer study of oridonin while clearly separating published findings from recommended validation experiments.

• BOP Reagent in Translational Prodrug Design

  2026-08-21

  A mechanistic and strategic guide to using BOP reagent in peptide and prodrug workflows, with a clear evidence bridge to carrier-free, ROS-responsive triterpene systems investigated for oral squamous cell carcinoma.

• DiscoveryProbe Bioactive Compound Library Plus for TSA

  2026-08-20

  Pair a broad, pre-dissolved small-molecule collection with thermal shift assay design to move from ligand discovery to pathway-level validation. The workflow combines bacterial sensor-protein biophysics, orthogonal binding confirmation, and cell-based follow-up for more defensible screening decisions.

• Novel Ziprasidone Impurity: Methods and Significance

  2026-08-20

  The reference study identified and structurally characterized methylene ziprasidone dimer, an unknown process-related impurity detected during ziprasidone hydrochloride scale-up. Its combined HPLC, HRMS, and multidimensional NMR workflow provides a practical model for investigating low-level impurities that may affect pharmaceutical quality assessment.

• APEX2 Enables Efficient TERT Expression in Stem Cells

  2026-08-19

  A 2024 preprint identifies APEX2 as a DNA repair enzyme required for efficient TERT expression and telomerase activity in human embryonic stem cells, with similar evidence in a melanoma cell line. Its RNA-seq and chromatin-binding results suggest that repair of damage-prone repetitive DNA within the TERT locus, rather than strong promoter occupancy, may connect APEX2 to gene regulation.

• Trelagliptin, RUNX2, and Osteoblast Differentiation

  2026-08-19

  The reference study identifies a previously underexplored effect of the DPP-4 inhibitor trelagliptin: promotion of osteoblastic differentiation and mineralization in MC3T3-E1 cells. Its data connect this phenotype to increased RUNX2 and AMPK signaling, offering a mechanistic rationale for further osteoporosis research while remaining limited to an in vitro model.

7848 records 1/524 page Next 12345 下5页 Last page